CGI Pharmaceuticals, Inc., a development-stage pharmaceutical company, discovers and develops small molecule therapeutics for multiple oncology and immunology-based indications. The company provides drug discovery and development programs, including Btk, a B-cell kinase for a range of AAID and oncology indications; and Syk, a regulator of mast cell, monocyte/macrophage, and B-cell functions. CGI Pharmaceuticals, Inc. was founded in 2000 as Cellular Genomics, Inc. and changed its name to CGI Pharmaceuticals, Inc. in September, 2005. The company is headquartered in Branford, Connecticut.
Gilead to buy CGI Pharm for $120M (fiercebiotech.com)